TCT 2019—Ixazomib maintenance therapy for multiple myeloma improves PFS


  • Tara Haelle
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • PFS improved 39% in patients with multiple myeloma (MM) taking ixazomib vs placebo after autologous stem cell transplantation (ASCT).

Why this matters

  • 29% of patients discontinue lenalidomide, the only approved maintenance therapy for MM after ASCT, for treatment-related adverse events (AEs).

Study design

  • Phase 3, double-blind, placebo-controlled TOURMALINE-MM3 trial randomly assigned 656 patients with MM to receive 3-4 mg oral proteasome inhibitor (PI) ixazomib (n=395) or placebo (n=261) after ASCT on days 1, 8, and 15 of 28-day cycles.
  • Therapy for 2 years or until progressive disease/intolerable toxicity.
  • Funding: Takeda.

Key results

  • At median 31 months follow-up, median PFS was significantly longer with ixazomib vs placebo (26.5 vs 21.3 months; HR, 0.72; 95% CI, 0.58-0.89; P=.002).
    • 54% of patients showed disease progression.
    • PFS significantly improved by 39% with ixazomib.
    • Observed across stage III, high-risk cytogenetics, PI-exposed, and PI-naive subgroups.
  • Deepened response rates with ixazomib vs placebo (relative risk, 1.41; 95% CI, 1.10-1.80; P=.004).
  • 12% ixazomib vs 7% placebo patients converted from minimal residual disease positivity to negativity.
  • AE discontinuation in 7% ixazomib vs 5% placebo. 
    • Grade ≥3 AEs in 42% ixazomib vs 26% placebo, primarily infections, gastrointestinal. disorders, neutropenia, and thrombocytopenia.
    • Serious AEs in 27% ixazomib vs 20% placebo.
    • New primary malignancy 3% in both groups.

Highlights from TCT Meetings 2019 

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit